# Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

> **NCT06762327** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Ensartinib

## Key facts

- **NCT ID:** NCT06762327
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06762327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06762327, "Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06762327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*